Table 2.
Comparison of antimicrobial resistance between CA and HA in the community-onset ESBL–producing E. coli: Univariate Analysis.
| Antimicrobial agent | CA (n = 57) | HA (n = 67) | OR (95% CI) | P value |
|---|---|---|---|---|
| Ampicillin-sulbactam | 46 (81) | 54 (81) | 1.002 (0.410–2.449) | 0.997 |
| Piperacillin-tazobactam | 0 (0) | 3 (4) | 0.160 (0.005–4.998) | 0.297 |
| Cefotaxime | 55 (96) | 67 (100) | 0.165 (0.004–6.892) | 0.344 |
| Ceftazidime | 38 (67) | 57 (85) | 0.361 (0.152–0.857) | 0.021 |
| Cefepime | 35 (61) | 49 (73) | 0.590 (0.276–1.260) | 0.173 |
| Meropenem | 0 (0) | 0 (0) | — | — |
| Ertapenem | 0 (0) | 0 (0) | — | — |
| Levofloxacin | 42 (74) | 53 (79) | 0.743 (0.323–1.710) | 0.486 |
| Aztreonam | 43 (75) | 60 (90) | 0.372 (0.139–0.994) | 0.049 |
| Amikacin | 0 (0) | 0 (0) | — | — |
| Gentamycin | 24 (42) | 34 (51) | 0.710 (0.349–1.446) | 0.346 |
| Trimethoprim-sulfamethoxazole | 30 (53) | 37 (55) | 0.902 (0.444–1.832) | 0.776 |
Data are no. (%) of resistant isolates. CA, community-associated; HA, healthcare-associated; OR, odds ratio; CI, confidence interval.